BioMarin Pharma (BMRN) Appoints Timothy P. Walbert to its Board

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the company's Board of Directors, effective Feb. 24, 2025.

Mr. Walbert led Horizon, a company that focused on medicines for rare diseases, from its founding in 2008 to acquisition by Amgen in 2023. Mr. Walbert is currently senior advisor, Amgen. Prior to Horizon, Mr. Walbert served as president and chief executive officer of IDM Pharma, which was acquired by Takeda in 2009, and before that held leadership positions at NeoPharm Inc. and Abbott (now AbbVie). He brings more than 30 years of industry experience across a number of pharmaceutical companies, including Pharmacia, Merck, Pfizer and Wyeth Ayerst. Mr. Walbert currently sits on the boards of directors of Sagimet Biosciences, Mirum Pharmaceuticals and Century Therapeutics.

"We are very pleased to welcome Tim to our Board of Directors," said Alexander Hardy, president and chief executive officer of BioMarin. "Tim is a deeply talented and well-respected leader with significant operational expertise, who brings a wealth of insight in commercializing medicines. Over the course of his career in the biopharmaceutical industry, he is someone who has been known for always putting patients first. The combination of his business acumen and patient-centered approach make him an ideal addition to our Board."

"I am pleased to join BioMarin's Board as the company works to deliver on the new strategy laid out last year focused on innovation, growth and value creation," said Mr. Walbert. "Throughout my time in the industry, I have focused on prioritizing the needs of patients and I look forward to working with BioMarin as the team advances new medicines for people with genetically defined conditions."

You May Also Be Interested In

• BioMarin completes acquisition of Amicus Therapeutics
• Starwood Capital promotes Qahir Madhany to head of Americas acquisitions
• Sanuwave Q2 2026 revenue tops revised guidance range